JP5960603B2 - 血糖値上昇抑制剤 - Google Patents
血糖値上昇抑制剤 Download PDFInfo
- Publication number
- JP5960603B2 JP5960603B2 JP2012542931A JP2012542931A JP5960603B2 JP 5960603 B2 JP5960603 B2 JP 5960603B2 JP 2012542931 A JP2012542931 A JP 2012542931A JP 2012542931 A JP2012542931 A JP 2012542931A JP 5960603 B2 JP5960603 B2 JP 5960603B2
- Authority
- JP
- Japan
- Prior art keywords
- epa
- blood glucose
- dha
- glucose level
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
(1)エイコサペンタエン酸(EPA)エステルまたはドコサヘキサエン酸(DHA)エステルを有効成分として含有し、食間に投与される、血糖値上昇抑制剤。
(2)食後2時間から食前1時間前までの食間に投与される、上記(1)に記載の血糖値上昇抑制剤。
(3)EPAエステルまたはDHAエステルが、EPAまたはDHAを構成脂肪酸とするトリグリセリド、またはEPAまたはDHAのC1−5アルキルエステルである、上記(1)または(2)に記載の血糖値上昇抑制剤。
(4)全脂肪酸中のEPAおよびDHAの合計含量が20重量%以上の精製魚油を有効成分とする、上記(1)〜(3)のいずれかに記載の血糖値上昇抑制剤。
(5)EPAエステルまたはDHAエステルを食間に投与することを含む、血糖値上昇抑制方法。
(6)EPAエステルまたはDHAエステルを食後2時間から食前1時間前までの食間に投与する、上記(5)に記載の血糖値上昇抑制方法。
(7)EPAエステルまたはDHAエステルが、EPAまたはDHAを構成脂肪酸とするトリグリセリド、またはEPAまたはDHAのC1−5アルキルエステルである、上記(5)または(6)に記載の血糖値上昇抑制方法。
(8)全脂肪酸中のEPAおよびDHAの合計含量が20重量%以上の精製魚油を有効成分とする、上記(5)〜(7)のいずれかに記載の血糖値上昇抑制方法。
空腹時血糖値が126mg/dL以下で、かつ糖負荷試験30分後の血糖値が130〜200mg/dLである健常人(男性4名、女性3名の計7名、43〜60歳)を対象としてOGTT後の血糖値上昇に対するEPAエステルまたはDHAエステルの効果を確認する試験を行った。
Claims (4)
- エイコサペンタエン酸のエステルまたはドコサヘキサエン酸のエステルを有効成分として含有し、食後2〜6時間であって次の食事の食前1時間前までの食間に経口投与される、食後血糖値上昇抑制剤。
- 食後3〜5時間であって次の食事の食前1時間前までの食間に投与される、請求項1に記載の食後血糖値上昇抑制剤。
- エイコサペンタエン酸のエステルまたはドコサヘキサエン酸のエステルが、エイコサペンタエン酸またはドコサヘキサエン酸を構成脂肪酸とするトリグリセリド、またはエイコサペンタエン酸またはドコサヘキサエン酸のC1−5アルキルエステルであり、医薬組成物または食品の成分として使用する、請求項1または2に記載の食後血糖値上昇抑制剤。
- 全脂肪酸中のエイコサペンタエン酸およびドコサヘキサエン酸の合計含量が20重量%以上の精製魚油を有効成分とする、請求項1〜3のいずれか1項に記載の食後血糖値上昇抑制剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010250870 | 2010-11-09 | ||
JP2010250870 | 2010-11-09 | ||
PCT/JP2011/075723 WO2012063820A1 (ja) | 2010-11-09 | 2011-11-08 | 血糖値上昇抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2012063820A1 JPWO2012063820A1 (ja) | 2014-05-12 |
JP5960603B2 true JP5960603B2 (ja) | 2016-08-02 |
Family
ID=46050962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012542931A Expired - Fee Related JP5960603B2 (ja) | 2010-11-09 | 2011-11-08 | 血糖値上昇抑制剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130303614A1 (ja) |
EP (1) | EP2638903A4 (ja) |
JP (1) | JP5960603B2 (ja) |
CN (2) | CN104814950A (ja) |
WO (1) | WO2012063820A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
US11033523B2 (en) | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
SG10201708952TA (en) | 2009-06-15 | 2017-12-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
LT3363433T (lt) | 2012-06-29 | 2021-02-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
JP6393501B2 (ja) * | 2014-04-03 | 2018-09-19 | 太陽化学株式会社 | 多価不飽和脂肪酸含有油脂の風味改善剤 |
KR101948398B1 (ko) | 2013-10-08 | 2019-02-14 | 타이요 카가꾸 가부시키가이샤 | 다가 불포화 지방산 함유 유지 조성물 |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
SG11202102872QA (en) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009500034A (ja) * | 2005-07-07 | 2009-01-08 | オーシャン・ニュートリション・カナダ・リミテッド | デリバリーデバイスを有する食料品およびその調製方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404483D0 (en) | 1994-03-08 | 1994-04-20 | Norsk Hydro As | Refining marine oil compositions |
JP4139544B2 (ja) * | 2000-03-06 | 2008-08-27 | 花王株式会社 | 血糖値低下剤 |
CN1180785C (zh) * | 2001-09-30 | 2004-12-22 | 中国药品生物制品检定所 | 海狗油作为制备治糖尿病药的应用 |
EP1603551A2 (en) * | 2003-03-05 | 2005-12-14 | Solvay Pharmaceuticals GmbH | Use of omega-3-fatty acids in the treatment of diabetic patients |
JP4757190B2 (ja) | 2004-03-01 | 2011-08-24 | ファルマフロンティア株式会社 | 血糖値の低下に供される医薬組成物 |
WO2007119811A1 (ja) | 2006-04-13 | 2007-10-25 | Nippon Suisan Kaisha, Ltd. | 高度不飽和脂肪酸濃縮油の製造方法 |
-
2011
- 2011-11-08 EP EP11839308.1A patent/EP2638903A4/en not_active Withdrawn
- 2011-11-08 US US13/884,089 patent/US20130303614A1/en not_active Abandoned
- 2011-11-08 JP JP2012542931A patent/JP5960603B2/ja not_active Expired - Fee Related
- 2011-11-08 CN CN201510115370.4A patent/CN104814950A/zh active Pending
- 2011-11-08 CN CN201180053961.3A patent/CN103338762B/zh not_active Expired - Fee Related
- 2011-11-08 WO PCT/JP2011/075723 patent/WO2012063820A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009500034A (ja) * | 2005-07-07 | 2009-01-08 | オーシャン・ニュートリション・カナダ・リミテッド | デリバリーデバイスを有する食料品およびその調製方法 |
Non-Patent Citations (2)
Title |
---|
JPN6015027255; Journal of Controlled Release Vol. 132, 2008, p. 99-104 * |
JPN6015027256; Biological and Pharmaceutical Bulletin Vol. 31, No. 5, 2008, p. 1021-1023 * |
Also Published As
Publication number | Publication date |
---|---|
CN104814950A (zh) | 2015-08-05 |
CN103338762A (zh) | 2013-10-02 |
US20130303614A1 (en) | 2013-11-14 |
EP2638903A4 (en) | 2013-12-04 |
WO2012063820A1 (ja) | 2012-05-18 |
JPWO2012063820A1 (ja) | 2014-05-12 |
CN103338762B (zh) | 2015-03-25 |
EP2638903A1 (en) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5960603B2 (ja) | 血糖値上昇抑制剤 | |
AU2001286576B2 (en) | Composition and method for treatment of hypertriglyceridemia | |
US20180085334A1 (en) | Methods of treating pediatric metabolic syndrome | |
JP2009051732A (ja) | Pparリガンド活性を有する組成物 | |
CN106470675A (zh) | 严重高甘油三酯血症的治疗 | |
EP2682116A1 (en) | Metabolic syndrome ameliorating agent | |
JP5718293B2 (ja) | Gip上昇抑制剤 | |
JP2017200910A (ja) | 血糖値上昇抑制剤 | |
JP4139544B2 (ja) | 血糖値低下剤 | |
JP2009019005A (ja) | 脂肪分解促進剤 | |
WO2011122389A1 (ja) | 糖尿病の予防又は治療用油脂組成物 | |
JP2011063557A (ja) | Ppar活性化剤 | |
JP5576699B2 (ja) | Gip上昇抑制剤 | |
JP4634065B2 (ja) | アディポネクチン低下抑制剤 | |
JP2004210652A (ja) | 糖尿病患者における脂質代謝改善剤 | |
WO2013005834A1 (ja) | 高純度epaを含有する抗肥満剤 | |
JP2008179609A (ja) | 血中アディポネクチン増加剤 | |
JP6053695B2 (ja) | 食欲抑制剤 | |
JP5317175B2 (ja) | インスリン抵抗性改善剤 | |
JP2015205846A (ja) | レプチン分泌促進剤 | |
JP2019127470A (ja) | リウマチ性疾患の治療用または予防用組成物 | |
JP2007246471A (ja) | 血中中性脂肪上昇抑制剤およびその製造方法 | |
JP2010241832A (ja) | アディポネクチン低下抑制剤 | |
CA2538494C (en) | Composition for modulating blood parameters | |
WO2015163091A1 (ja) | 不飽和脂肪酸の吸収促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150707 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150902 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151210 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160226 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160226 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160609 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5960603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |